The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice
(2023)
Journal Article
Gu, Y., Avolio, E., Alvino, V. V., Thomas, A. C., Herman, A., Miller, P. J., …Madeddu, P. (in press). The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice. Cardiovascular Diabetology, 22(1), https://doi.org/10.1186/s12933-023-01955-9